When these many studies on the preclinical development of BDNF, CNTF, GDNF and the non-traditional neurotrophic factors are considered in total, there are still many unresolved questions related to their potential effectiveness as ALS therapies. The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.